Pyxis Oncology, Inc. Variable Lease, Cost
Pyxis Oncology, Inc. (PYXS) reported Variable Lease, Cost of $319.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-13
- Pyxis Oncology, Inc. variable lease, cost for the quarter ending 2026-06-30 was $319.00K, a 14.93% decline year-over-year.
- Pyxis Oncology, Inc. variable lease, cost for the quarter ending 2026-03-31 was $255.00K, a 363.64% increase year-over-year.
- Pyxis Oncology, Inc. variable lease, cost for the quarter ending 2025-12-31 was $305.00K, a 19.31% decline year-over-year.
- Pyxis Oncology, Inc. variable lease, cost for the quarter ending 2025-09-30 was $312.00K, a 22.39% decline year-over-year.
- Pyxis Oncology, Inc. variable lease, cost for fiscal 2025 was $1.05M, a 39.72% decline from fiscal 2024.
- Pyxis Oncology, Inc. variable lease, cost for fiscal 2024 was $1.74M, a 130.68% increase from fiscal 2023.
- Pyxis Oncology, Inc. variable lease, cost for fiscal 2023 was $753.00K, a 522.31% increase from fiscal 2022.
- Pyxis Oncology, Inc. variable lease, cost for fiscal 2022 was $121.00K, a 61.33% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 3 month as first filed | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $319.00K 10-Q · filed 2026-08-13 | $574.00K 10-Q · filed 2026-08-13 | $879.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.19M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $255.00K 10-Q · filed 2026-05-14 | $560.00K derived: sum of 2 quarters · filed 2026-05-14 | $872.00K derived: sum of 3 quarters · filed 2026-05-14 | $1.25M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $305.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $617.00K derived: sum of 2 quarters · filed 2026-03-23 | $992.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.05M 10-K · filed 2026-03-23 | |
| 2025-09-30 | $312.00K 10-Q · filed 2025-11-03 | $687.00K derived: sum of 2 quarters · filed 2026-08-13 | $742.00K 10-Q · filed 2025-11-03 | $1.12M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $375.00K 10-Q · filed 2026-08-13 | $430.00K 10-Q · filed 2026-08-13 | $808.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.21M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $55.00K 10-Q · filed 2026-05-14 | $433.00K derived: sum of 2 quarters · filed 2026-05-14 | $835.00K derived: sum of 3 quarters · filed 2026-05-14 | $1.25M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $378.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $780.00K derived: sum of 2 quarters · filed 2026-03-23 | $1.19M derived: sum of 3 quarters · filed 2026-03-23 | $1.74M 10-K · filed 2026-03-23 | |
| 2024-09-30 | $402.00K 10-Q · filed 2025-11-03 | $814.00K derived: sum of 2 quarters · filed 2025-11-03 | $1.36M 10-Q · filed 2025-11-03 | $1.59M derived: sum of 4 quarters · filed 2025-11-03 | |
| 2024-06-30 | $412.00K 10-Q · filed 2025-08-14 | $957.00K 10-Q · filed 2025-08-14 | $1.19M derived: sum of 3 quarters · filed 2025-08-14 | $1.42M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $539.00K 10-Q · filed 2025-05-15 | $500.00K 10-Q · filed 2024-05-14 | $774.00K derived: sum of 2 quarters · filed 2025-05-15 | $1.00M derived: sum of 3 quarters · filed 2025-05-15 | $1.23M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $235.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $465.00K derived: sum of 2 quarters · filed 2025-03-18 | $695.00K derived: sum of 3 quarters · filed 2025-03-18 | $753.00K 10-K · filed 2025-03-18 | |
| 2023-09-30 | $230.00K 10-Q · filed 2024-11-12 | $460.00K derived: sum of 2 quarters · filed 2024-11-12 | $518.00K 10-Q · filed 2024-11-12 | $465.00K derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $230.00K 10-Q · filed 2024-08-14 | $288.00K 10-Q · filed 2024-08-14 | $235.00K derived: sum of 3 quarters · filed 2024-08-14 | $247.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | $5.00K derived: sum of 2 quarters · filed 2024-05-14 | $17.00K derived: sum of 3 quarters · filed 2024-05-14 | $56.00K derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $17.00K derived: sum of 2 quarters · filed 2024-03-21 | $56.00K derived: sum of 3 quarters · filed 2024-03-21 | $121.00K 10-K · filed 2024-03-21 | |
| 2022-09-30 | $12.00K 10-Q · filed 2023-11-07 | $51.00K derived: sum of 2 quarters · filed 2023-11-07 | $116.00K 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $39.00K 10-Q · filed 2023-08-11 | $104.00K 10-Q · filed 2023-08-11 | |||
| 2021-12-31 | $75.00K 10-K · filed 2023-03-22 | ||||
| 2020-12-31 | $70.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |